Valuation : Kamada Ltd.

Market Cap 1.44B 474M 408M 384M 350M 655M 45.14B 658M 4.56B 1.76B 23B 1.78B 1.74B 72.85B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.44B 474M 408M 384M 350M 655M 45.14B 658M 4.56B 1.76B 23B 1.78B 1.74B 72.85B EV / Sales 2026 *
2.37x
EV / Sales 2027 * 2.13x
Free-Float
54.48%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2015
Director of Finance/CFO 56 31/12/2017
Chief Operating Officer 54 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.28% - - 476M
-0.33%-5.21%+45.12%-2.77% 80.91B
-1.92%-4.35%-20.42%-37.50% 60.46B
-3.36%-10.08%+454.19%+25.98% 56.02B
+0.83%-3.26%-9.28%+30.44% 49.63B
-1.11%-7.21%-2.15%+147.94% 45.88B
-0.83%-5.36%+46.75%-18.63% 31.4B
+1.29%-2.19%+47.21%+96.95% 25.22B
-1.12%-5.36%-2.51%+153.52% 22.25B
-3.02%-2.59%+60.23%+104.24% 16.59B
Average -0.49%-2.83%+68.79%+55.57% 43.15B
Weighted average by Cap. -0.31%-3.04%+79.58%+36.74%

Financials

2026 *2027 *
Net sales 606M 200M 172M 162M 148M 276M 19.04B 277M 1.92B 743M 9.7B 751M 735M 30.73B 673M 222M 191M 180M 164M 307M 21.16B 308M 2.14B 825M 10.78B 835M 817M 34.15B
Net income 84.8M 28.01M 24.1M 22.69M 20.68M 38.68M 2.66B 38.84M 269M 104M 1.36B 105M 103M 4.3B 104M 34.39M 29.59M 27.86M 25.39M 47.5M 3.27B 47.69M 330M 128M 1.67B 129M 126M 5.28B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-